Institute of Primary Health Care (BIHAM), University of Bern, 3012 Bern, Switzerland.
Materno-Fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Viruses. 2023 Apr 29;15(5):1090. doi: 10.3390/v15051090.
With COVID-19 vaccination hesitancy at around 50% in the obstetric population, it is critical to identify which women should be addressed and how. Our study aimed to assess COVID-19 vaccination willingness among pregnant and postpartum women in Europe and to investigate associated determinants. This study was a cross-sectional, web-based survey conducted in Belgium, Norway, Switzerland, The Netherlands, and United Kingdom (UK) in June-August 2021. Among 3194 pregnant women, the proportions of women vaccinated or willing to be vaccinated ranged from 80.5% in Belgium to 21.5% in Norway. The associated characteristics were country of residence, chronic illness, history of flu vaccine, trimester of pregnancy, belief that COVID-19 is more severe during pregnancy, and belief that the COVID-19 vaccine is effective and safe during pregnancy. Among 1659 postpartum women, the proportions of women vaccinated or willing to be vaccinated ranged from 86.0% in the UK to 58.6% in Switzerland. The associated determinants were country of residence, chronic illness, history of flu vaccine, breastfeeding, and belief that the COVID-19 vaccine is safe during breastfeeding. Vaccine hesitancy in the obstetric population depends on medical history and especially on the opinion that the vaccine is safe and on the country of residence.
在产科人群中，对 COVID-19 疫苗的犹豫率约为 50%，因此确定应针对哪些女性以及如何针对她们进行疫苗接种至关重要。我们的研究旨在评估欧洲孕妇和产后妇女对 COVID-19 疫苗的接种意愿，并调查相关决定因素。本研究是一项于 2021 年 6 月至 8 月在比利时、挪威、瑞士、荷兰和英国（UK）进行的横断面、基于网络的调查。在 3194 名孕妇中，接种或愿意接种疫苗的妇女比例从比利时的 80.5%到挪威的 21.5%不等。相关特征包括居住国家、慢性病、流感疫苗接种史、妊娠阶段、认为 COVID-19 在怀孕期间更严重，以及认为 COVID-19 疫苗在怀孕期间有效且安全。在 1659 名产后妇女中，接种或愿意接种疫苗的妇女比例从英国的 86.0%到瑞士的 58.6%不等。相关决定因素包括居住国家、慢性病、流感疫苗接种史、母乳喂养以及认为 COVID-19 疫苗在母乳喂养期间是安全的。产科人群中的疫苗犹豫取决于病史，尤其是对疫苗安全性的看法以及居住国家。
